News Merck bags adjuvant okay for Keytruda in melanoma Checkpoint inhibitors have already revolutionised the treatment of advanced melanoma, and Merck & Co has just claimed approval for even earlier use of its Keytruda product in Europe.
News BMS files Opdivo in post-surgery setting Opdivo performed better than BMS' Yervoy in clinical trial.
News Immunocore hires Lilly's Hotchkiss as chief commercial offic... UK biotech leading in the nascent field of TCR immunotherapy has appointed Andrew Hotchkiss as its new Chief Commercial Officer.
News Opdivo and Tafinlar+Mekinst hailed in earlier melanoma treat... Two new regimens look set to transform treatment to delay melanoma returning in patients after surgery.
News NICE recommends Amgen’s melanoma treatment after price cut Drug only approved when systemic immunotherapies are not suitable
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.